Wednesday, January 11, 2023 1:57:59 PM
The idea is not that the FDA will drag this out for years. It is that they can place obstacles where needed if BP needs it. Look at the news that just came out about Pfizer increasing their price point.
If I (BP) know that someone (you/RVV) may potentially have something that can open the eyes of people and take them away from my cash cow, I am going to use whatever power & influence I have to make sure that gets delayed until I can milk as much out for my product as possible.
Looking at the way things have taken place for Revive. They originally wanted to test 1000 people, this was agreed upon with the FDA. They struggled to even get a foothold into hospitals to get the number they have now. Most hospitals (like the ones in California) were already "talked to". When I asked about test programs, I was told nothing like that would be allowed. They were already told what they could use and nothing else was being allowed.
Watch Dopesick and say with a straight face (or in full sincerity) that the FDA does not play favorites, does not create obstacles, or for that matter truly has the publics best interest in mind.
If I (BP) know that someone (you/RVV) may potentially have something that can open the eyes of people and take them away from my cash cow, I am going to use whatever power & influence I have to make sure that gets delayed until I can milk as much out for my product as possible.
Looking at the way things have taken place for Revive. They originally wanted to test 1000 people, this was agreed upon with the FDA. They struggled to even get a foothold into hospitals to get the number they have now. Most hospitals (like the ones in California) were already "talked to". When I asked about test programs, I was told nothing like that would be allowed. They were already told what they could use and nothing else was being allowed.
Watch Dopesick and say with a straight face (or in full sincerity) that the FDA does not play favorites, does not create obstacles, or for that matter truly has the publics best interest in mind.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
